{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:52:01Z","timestamp":1776577921045,"version":"3.51.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Stereotactic body radiotherapy is a new treatment modality for long bone metastasis and has not been discussed in literature. We aimed to clarify stereotactic body radiotherapy outcomes for long bone metastases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data of patients receiving stereotactic body radiotherapy for long bone metastases (July 2016\u2013November 2020) were retrospectively reviewed. The prescribed dose was 30 or 35\u00a0Gy in five fractions. The endpoints were local failure and adverse effects. Local failure was defined as radiological tumor growth within the irradiation field. Adverse effects were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nineteen osseous lesions in 17 patients were assessed. The target lesions included 13 femoral, 4 humeral and 2 radial lesions. The median follow-up duration was 14 (range, 3\u201362) months. The 12- and 18-month local failure rates were 0 and 11%, respectively. Following 2 and 46\u00a0months of stereotactic body radiotherapy, two lesions (11%) resulted in painful femoral fractures (grade 3). Both patients underwent bipolar hip arthroplasty and could walk normally after surgery. In the late phase, one patient developed radiculopathy (almost complete paralysis of grasp) and another developed grade 2 limb edema. Other grade 2 or more severe acute and late toxicities were not observed during the follow-up period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Stereotactic body radiotherapy for long bone metastases achieved excellent local control and caused two femoral fractures. We argue that stereotactic body radiotherapy for curative intent should not be contraindicated in long bone oligometastasis because fractures do not directly contribute to life expectancy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyab164","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T20:39:29Z","timestamp":1633034369000},"page":"47-52","source":"Crossref","is-referenced-by-count":6,"title":["Fracture risk following stereotactic body radiotherapy for long bone metastases"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-3795","authenticated-orcid":false,"given":"Kei","family":"Ito","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"},{"name":"Department of Radiological Sciences, Komazawa University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"2022010310234688800_ref1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3171\/2017.1.SPINE16684","article-title":"Stereotactic body radiotherapy for de novo spinal metastases: systematic review","volume":"27","author":"Husain","year":"2017","journal-title":"J Neurosurg Spine"},{"key":"2022010310234688800_ref2","first-page":"58","article-title":"Stereotactic body radiation therapy for non-spine bone metastases--a review of the literature","volume":"5","author":"Bedard","year":"2016","journal-title":"Ann Palliat Med"},{"key":"2022010310234688800_ref3","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ijrobp.2016.03.027","article-title":"Postoperative stereotactic body radiation therapy (SBRT) for spine metastases: a critical review to guide practice","volume":"95","author":"Redmond","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022010310234688800_ref4","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"2022010310234688800_ref5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3171\/2020.5.SPINE191383","article-title":"Vertebral body fracture rates after stereotactic body radiation therapy compared with external-beam radiation therapy for metastatic spine tumors","volume":"33","author":"Vargas","year":"2020","journal-title":"J Neurosurg Spine"},{"key":"2022010310234688800_ref6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rpor.2019.12.018","article-title":"Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: classification into five treatment groups","volume":"25","author":"Ito","year":"2020","journal-title":"Rep Pract Oncol Radiother"},{"key":"2022010310234688800_ref7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijrobp.2017.08.045","article-title":"Patterns of intraosseous recurrence after stereotactic body radiation therapy for coxal bone metastasis","volume":"100","author":"Ito","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022010310234688800_ref8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ijrobp.2011.02.008","article-title":"Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases","volume":"82","author":"Chow","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022010310234688800_ref9","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0"},{"key":"2022010310234688800_ref10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1302\/0301-620X.86B4.14703","article-title":"Comparative analysis of risk factors for pathological fracture with femoral metastases","volume":"86-B","author":"van der Linden","year":"2004","journal-title":"J Bone Joint Surg Br"},{"key":"2022010310234688800_ref11","first-page":"256","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures","author":"Mirels","year":"1989","journal-title":"Clin Orthop Relat Res"},{"key":"2022010310234688800_ref12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1748-717X-7-159","article-title":"Predictors of radiotherapy induced bone injury (ribi) after stereotactic lung radiotherapy","volume":"7","author":"Taremi","year":"2012","journal-title":"Radiat Oncol"},{"key":"2022010310234688800_ref13","doi-asserted-by":"crossref","first-page":"20170196","DOI":"10.1259\/bjr.20170196","article-title":"A dosimetric parameter to limit chest wall toxicity in sabr of nsclc","volume":"90","author":"Jumeau","year":"2017","journal-title":"Br J Radiol"},{"key":"2022010310234688800_ref14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.radonc.2017.01.004","article-title":"Dose\u2013effect analysis of radiation induced rib fractures after thoracic sbrt","volume":"123","author":"Stam","year":"2017","journal-title":"Radiother Oncol"},{"key":"2022010310234688800_ref15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2022010310234688800_ref16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10585-021-10105-y","article-title":"Novel approach involving stereotactic body radiotherapy followed by intramedullary nail placement for long bone metastases: a case report","volume":"38","author":"Ito","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"2022010310234688800_ref17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clon.2015.07.006","article-title":"Bone health and pelvic radiotherapy","volume":"27","author":"Higham","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2022010310234688800_ref18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/neuros\/nyx493","article-title":"Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors","volume":"83","author":"Faruqi","year":"2018","journal-title":"Neurosurgery"},{"key":"2022010310234688800_ref19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases","volume":"127","author":"Erler","year":"2018","journal-title":"Radiother Oncol"},{"key":"2022010310234688800_ref20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3747\/co.27.5959","article-title":"Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review","volume":"27","author":"Voruganti","year":"2020","journal-title":"Curr Oncol"},{"key":"2022010310234688800_ref21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ijrobp.2020.05.013","article-title":"Radiation-induced insufficiency fractures after pelvic irradiation for gynecologic malignancies: a systematic review","volume":"108","author":"Razavian","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022010310234688800_ref22","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic acid lung cancer and other solid Tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022010310234688800_ref23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/1\/47\/42011494\/hyab164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/1\/47\/42011494\/hyab164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T10:30:12Z","timestamp":1641205812000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/1\/47\/6396792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,10,14]]},"published-print":{"date-parts":[[2022,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab164","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2021,10,14]]}}}